Amalgamated Financial
ESPR icon

Amalgamated Financial’s Esperion Therapeutics ESPR Stock Holding History

Amalgamated Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$34K Buy
+7,266
New +$31.2K ﹤0.01% 2574

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Amalgamated Financial's ESPR Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Esperion Therapeutics (ESPR) in Q1 2022: 7,266 shares worth $34K. The stake represents ﹤0.01% of the portfolio and ranks #2574 among its holdings.

132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Amalgamated Financial held 7,266 shares of Esperion Therapeutics worth $34K as of Q1 2022.
  • Esperion Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Esperion Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2574 holding.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.